US President Donald Trump’s ever-evolving stance on tariffs may be rattling the world and also has pharma on tenterhooks, but going down that path for generic medicines may be a doubled-edged sword or even counterproductive, at least in the short term.
While pharmaceuticals were exempted in Trump’s initial reciprocal tariff salvo, his subsequent warning speaking to reporters on Air Force One that pharma could see tariffs at levels “never seen before” suggests that industry is still in unpredictable terrain